Nicotine in Neurodegenerative and Neuropsychiatric Disorders: Mechanisms and Clinical Evidence

Glutamatergic Dysregulation in Depression, Schizophrenia, and Addiction: Mechanisms and Therapeutic Strategies

Glutamate, the principal excitatory neurotransmitter in the brain, plays a central role in neurotransmission, synaptic plasticity, and cognitive function. Dysregulation of glutamatergic signaling is implicated in depression, schizophrenia (SCZ), and addiction. N-methyl-Daspartate receptor/α-amino-3-hydroxy-5-methyl-4-...

Metabotropic Glutamate Receptors as Therapeutic Targets for Nicotine Addiction

Advances in Targeting Central Cholinergic Dysfunction for Neurodegenerative Diseases: From Pharmacotherapy to Neuromodulation

The integration of sophisticated pharmacological agents with circuit‐level neuromodulation represents the next frontier in treating cholinergic dysfunction across the spectrum of neurodegenerative disorders, advancing the therapeutic goal from chemical enhancement to circuit repair and regeneration.

New and emerging therapeutics and molecular targets for attention-deficit hyperactivity disorder.

INTRODUCTION Attention‑deficit hyperactivity disorder (ADHD) is defined by persistent, impairing, and developmentally inappropriate patterns of inattention and/or hyperactivity/impulsivity. ADHD is a multifactorial, partially heritable and polygenic disorder, involving multiple biological pathways and implicating many...

Emerging Advances in Neuropharmacology: Novel Therapeutic Targets for Neurodegenerative Disorders

Neurodegenerative diseases are a heterogeneous group of chronic and progressive disorders, which are characterized by selective neuronal destruction, synaptic malfunction and progressive cognitive and locomotor dysfunction. The major ones are Alzheimer disease, Parkinson disease, Huntington disease, and amyotrophic lat...

Neuropharmacological Interventions in Alzheimer’s Disease: Current and Emerging Approaches

Alzheimer’s Disease (AD) is a neurodegenerative disorder with progressive cognitive decline, β-amyloid plaques, neurofibrillary tangles, oxidative stress, and neuroinflammatory responses. So far, the pathogenesis of AD has been explained by the cholinergic hypothesis, amyloid cascade hypothesis, and tau protein dys...